Acquisitions23 Sept 2026, 06:00 pm
Jagsonpal Pharma Acquires Group Pharma's Wellness Portfolio for ₹46.7 Cr
AI Summary
Jagsonpal Pharmaceuticals Ltd. has entered into a Business Transfer Agreement with Group Pharmaceuticals Limited to acquire its Wellness Portfolio on a going-concern basis via slump sale. The acquisition, valued at an initial ₹23.7 crores with an additional consideration of up to ₹23.0 crores linked to FY 2027-28 sales (total cap ₹46.7 crores), is expected to be completed by November 1, 2026. This strategic move aims to strengthen Jagsonpal's pharmaceutical portfolio, enhance its presence in key therapeutic segments, and expand its market reach. The acquired portfolio had a turnover of ₹24.6 Crores in FY 2025-26 and operates in the pharmaceutical industry.
Key Highlights
- Jagsonpal Pharmaceuticals acquires Group Pharma's Wellness Portfolio.
- Transaction value up to ₹46.7 Crores, including performance-based component.
- Acquisition strengthens product portfolio and market presence.
- Deal expected to close by November 1, 2026.
- Turnover of acquired portfolio was ₹24.6 Crores in FY26.
Price Impact
More from JAGSNPHARM